Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of brivekimig in adults with moderate to severe ulcerative colitis
CTR20253575Phase 2Active
- Sponsor
- Sanofi
- Start
- Jan 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of brivekimig in autoimmune colitis, sponsored by Sanofi. Started Jan 2026; status: active.
02
Drugs
brivekimig
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20253575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253575.